Glaucoma is currently the second leading cause of blindness throughout the world. The goal of glaucoma treatment is to stop or slow disease progression. Current glaucoma medications achieve this almost exclusively through reduction of intraocular pressure (IOP). Unfortunately, even with appropriate use of currently available medications, many people with glaucoma will still experience vision loss. Intraocular pressure is the only known modifiable risk factor for patients with glaucoma, so improvements in patient outcomes rely on tight IOP control and patient adherence to therapy. In this educational activity, leading clinicians review established and new therapeutic agents for patients with glaucoma, including the recent clinical evidence for their safety and efficacy. In addition, discussion will include the extent to which patient adherence has a negative impact on the delivery of effective therapy for glaucoma
SPECTRALIS spectral domain optical coherence tomography (SD-OCT) is a fast, non-invasive method of examining the posterior section of the eye. Apart from an optimal imaging technique that aids in diagnosis, it also offers a unique AutoRescan function which allows for reproducible measurements necessary for optimal monitoring of disease.
The qualitative evaluation of OCT images makes it possible to accurately assign pathological changes to the individual layers of the retina.
This guide will help you to both systematically evaluate OCT images and to describe clinical observations visualized by such images in a straight forward and efficient manner.
Purpose: To determine adherence to face-down positioning (FDP) among patients who underwent vitrectomy and gas tamponade for macular hole (MH) repair.
Method: A total of 69 patients (37 females and 32 males) who underwent primary vitrectomy for MH repair were studied. Nurses recorded whether the patient complied with FDP each time they examined the patient. FDP score was obtained from the nursing records; patients were given a score of 1 if they complied with the FDP and 0 if they did not. The score was recorded four times per day for the first 3 postoperative days. A perfect FDP score was 12.
Results: The mean ± standard deviation of the FDP scores was 10.6±1.8 (range: 4–12). Overall, 32 (46.4%) patients scored a perfect 12, and 7 (10.1%) patients scored <8. Failure of the MH closure was observed in only one patient (1.4%), who showed the poorest adherence to FDP (score =4). Consequently, the closure rate in patients with FDP score <7 (2/3, 66.7%) was significantly lower than in patients with an FDP score ≥7 (66/66, 100%) (P<0.05, Fisher’s exact probability test).
Conclusion: While adherence to FDP after MH surgery was better than that observed after vitrectomy for rhegmatogenous retinal detachments in our previous study, the percentage of patients with FDP scores <8 did not differ. Statistically, the poor adherence to FDP can negatively impact the effectiveness of the surgery for MH repair.
The capsulotomy has a fascinating history – one tinged with jealousy, rivalry, fashion, evolution, revolution and even nationalistic pride – and it’s a story that’s got a great deal more to tell.
It started with the Frenchman, Jaques Daviel, who ushered in the modern era of cataract surgery, abandoning couching (Box 1) for the first extracapsular cataract extraction (ECCE; Box 2). The British, for predominantly patriotic reasons, preferred couching (Box 3), but ECCE was always going to win out. Albrecht von Graefe improved it in 1850 with his eponymous knife (Box 4) and, extraordinarily, his technique lasted for over a century. That’s not to say that competing approaches weren’t developed along the way – Ignacio Barraquer devised the suction cup-based erisophake in 1917, which enabled rapid intracapsular extraction of the lens (Box 5), but its uptake was limited. So the von Graefe method persisted into the 1970s.
Determining target intraocular pressure (IOP) in glaucoma patients is multifaceted, requiring attention to many different factors such as glaucoma type, severity of disease, age, race, family history, corneal thickness and hysteresis, and initial IOP. Even with all these variables accounted for, there are still patients who have progression of the disease despite achieving target IOP. Intraocular pressure variability has been identified as a potential independent risk factor for glaucoma progression but is currently difficult to quantify in individual patients. New technologies enabling measurement of both diurnal and nocturnal IOP may necessitate modifying our concept of target pressure.
Abstract: Inflammatory bowel disease (IBD) is a chronic and heterogeneous disorder characterized by remitting and relapsing periods of activity. Pharmacogenetics refers to the study of the effect of inheritance on individual variation in drug responses. Several drug-related markers in IBD patients have been identified in order to predict the response to medical treatment including biological therapy as well as the reduction of adverse events. In the future, the treatment of IBD should be personalized in its specific profile to provide the most efficacious treatment with lack of adverse events.
Focused Ultrasound for Glaucoma: comparing clinical results and perspectives for patients in Western and Asian countries
Keith Barton, MD, Moor elds Eye Hospital, London, United Kingdom Florent Aptel, MD, Grenoble University Hospital, France
High-intensity Focused Ultrasound : mechanisms of action
Ingeborg Stalmans, MD, Leuven University Hospital, Belgium Clinical experience on refractory and non-refractory open-angle glaucoma patients
Ronnie George, MD, Sankara Nethralaya Hospital, Chennai, India Clinical experience of focused ultrasound in the Indian population
Jian Ge, MD, Zhongshan Ophthalmic Center, Sun Yat-Sen University Hospital, Guangzhou, China
Treatment outcomes on angle-closure glaucoma in Chinese patients
In a bid to provide affordable technology to resource-poor countries, the humble ophthalmoscope has had a makeover – or rather a ‘makeunder.’ With a simplified design, a patented LED light source and a solar panel, the Arclight is a pocket instrument the size of a marker pen and lighter than an AA battery. The device is significantly lower in cost than the traditional ophthalmoscope – and its potential to serve those who need it most was quickly recognized by global health leaders. More than 8,000 devices have been distributed across the world – with the International Agency for the Prevention of Blindness (IAPB) based in London, UK, helping with marketing and sales to many countries including Malawi, Ethiopia, Fiji and Indonesia.
Выйдет в свет точно по расписанию! Номер посвящен перфузионному давлению при глаукоме. Публикация этого материла стала возможной благодаря достигнутому сотрудничеству с международным журналом Glaucoma Today (USA) и с личного согласия авторов
Purpose: The aim of this study was to estimate the efficacy of intense pulsed light (IPL), followed by meibomian gland expression (MGX), for reducing the number and severity of signs and symptoms of dry eye disease (DED) secondary to meibomian gland dysfunction (MGD)
Trachoma affects approximately 150 million people worldwide, and the ICO is dedicated to its eradication. The ICO outlined this commitment in our 2009 Bahrain Declaration on Trachoma and Trichiasis Surgery. The declaration builds on the ICO’s long history of leadership in the prevention of trachomatous blindness:
The organization that became the ICO grew out of actions in 1857 to address the problem of trachoma in Europe.
In 1928, the ICO led international efforts to focus on trachoma around the world.
The ICO is a founding member of the International Agency for Prevention of Blindness.
The ICO is a partner in VISION 2020: The Right to Sight.
ICO President Prof. Hugh Taylor literally wrote the book on trachoma.
Сайт основан 20 декабря 2000 года
Авторские права на дизайн и всю информацию веб-сайта www.eyenews.ru (www.glaucomanews.ru www.corneanews.ru, www.cataractanews.ruwww.retinanews.ru www.айньюс.рф www.hrtclubrussia.ru), а также на подбор и расположение материалов принадлежат учредителю и редакции вышеуказаных порталов. Использование материалов сайтов разрешено только с письменного разрешения учредителя и редакции вышеуказанных сайтов. Воспроизведение фотографий, статей и новостей, абстрактов и прочего контента любым способом без письменного разрешения запрещено и влечет ответственность, предусмотренную законодательством о защите авторских прав. Запрещается автоматизированное извлечение информации сайта любыми сервисами без официального разрешения учредителя либо редакции сайтов. При цитировании материалов ссылка наwww.eyenews.ru и другие вышеуказанные сайты обязательна.